You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Analysis of recent sufficient and insufficient coverage at first and most recent interview

From: Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis

  First interview <100 %, n (%) First interview ≥100 %, n (%) Chi-squared p-value Most recent interview <100 %, n (%) Most recent interview ≥100 % Chi-squared p-value AORa at first interview, AOR (95 % CI) AOR p-value
Sex
Female 27 (36 %) 84 (39 %) 0.673 23 (32 %) 81 (38 %) 0.393 1  
Male 47 (64 %) 130 (61 %)   47 (68 %) 132 (62 %)   1.37 (0.61, 3.09) 0.442
Indigenous status
No 66 (92 %) 200 (93 %) 0.606 62 (91 %) 202 (95 %) 0.270 1  
Yes 6 (8 %) 14 (7 %)   6 (9 %) 11 (5 %)   1.04 (0.26, 4.20) 0.956
WHO definition of youth
≤24 years 11 (15 %) 41 (19 %) 0.408 3 (4 %) 9 (4 %) 0.983 1  
>24 years 63 (85 %) 173 (81 %)   67 (96 %) 204 (96 %)   0.77 (0.23, 2.51) 0.661
Highest level of education
<yr10 23 (31 %) 63 (29 %) 0.515 15 (22 %) 59 (28 %) 0.620 1  
Year 10–11 26 (36 %) 92 (43 %)   26 (38 %) 74 (35 %)   0.56 (0.23, 1.39) 0.210
Year 12/higher educ/trade 24 (33 %) 59 (28 %)   28 (40 %) 80 (37 %)   1.61 (0.63, 4.13) 0.324
Employment status
No 63 (85 %) 175 (82 %) 0.511 56 (80 %) 168 (79 %) 0.840 1  
Yes 11 (15 %) 39 (18 %)   14 (20 %) 45 (21 %)   0.94 (0.29, 3.01) 0.919
Weekly income
<$400 52 (70 %) 144 (67 %) 0.635 35 (50 %) 113 (53 %) 0.657 1  
≥$400 22 (30 %) 70 (33 %)   35 (50 %) 100 (47 %)   0.97 (0.40, 2.35) 0.943
Stable accommodation
No 16 (22 %) 31 (14 %) 0.152 17 (25 %) 34 (16 %) 0.104 1  
Yes 58 (78 %) 183 (86 %)   52 (75 %) 179 (84 %)   1.03 (0.39, 2.71) 0.956
Country of birth
Other 17 (24 %) 40 (19 %) 0.366 18 (26 %) 36 (17 %) 0.081 1  
Australia 55 (76 %) 174 (81 %)   50 (74 %) 177 (83 %)   0.96 (0.37, 2.46) 0.934
Injecting career
<13 years 32 (45 %) 96 (45 %) 0.951 31 (46 %) 45 (21 %) <0.001* 1  
≥13 years 40 (55 %) 118 (55 %)   37 (54 %) 168 (79 %)   0.65 (0.28, 1.53) 0.325
Heroin injection (past month)
No 9 (12 %) 38 (18 %) 0.262 10 (14 %) 39 (18 %) 0.440 1  
Yes 65 (88 %) 176 (82 %)   60 (86 %) 174 (82 %)   2.30 (0.70, 7.56) 0.171
Methamphetamine injection (past month)
 No 40 (54 %) 141 (66 %) 0.069 20 (29 %) 118 (55 %) <0.001* 1  
Yes 34 (46 %) 73 (34 %)   50 (71 %) 95 (45 %)   1.94 (0.86, 4.39) 0.112
Hazardous drinking scale score (8 point cut-off)
abstinent 24 (33 %) 71 (33 %) 0.588 28 (40 %) 85 (40 %) 0.675 1  
<8 points 27 (37 %) 90 (42 %)   23 (31 %) 77 (36 %)   0.82 (0.34, 1.98) 0.656
≥8 points 22 (30 %) 52 (25 %)   20 (29 %) 51 (24 %)   1.66 (0.63, 4.36) 0.304
Current OST prescription
No 35 (47 %) 86 (40 %) 0.199 45 (64 %) 86 (40 %) 0.001* 1  
Yes 29 (53 %) 127 (60 %)   25 (36 %) 127 (60 %)   1.02 (0.49, 2.11) 0.952
BBV-TRAQ-SV injecting risk scale score (continuous measure)
Mean 8.91 6.04 0.083 9.64 5.58 0.022* 1.01 (0.98, 1.03) 0.652
Receptive sharing (past month)
No 58 (78 %) 193 (91 %) 0.006* 57 (81 %) 191 (90 %) 0.054 1  
Yes 16 (22 %) 20 (9 %)   13 (19 %) 21 (10 %)   1.01 (0.31, 3.36) 0.982
Injecting others (past month)
No 56 (76 %) 173 (81 %) 0.343 60 (86 %) 184 (86 %) 0.888 1  
Yes 18 (24 %) 41 (19 %)   10 (14 %) 29 (14 %)   1.20 (0.47, 3.05) 0.699
Injected by others (past month)
No 66 (89 %) 186 (87 %) 0.610 68 (97 %) 192 (90 %) 0.063 1  
Yes 8 (11 %) 28 (13 %)   2 (3 %) 21 (10 %)   0.32 (0.69, 1.50) 0.148
Injecting more than usual (past six months)
No 45 (61 %) 133 (62 %) 0.838 38 (54 %) 144 (68 %) 0.039* 1  
Yes 29 (39 %) 81 (38 %)   32 (46 %) 68 (32 %)   1.27 (0.59, 2.76) 0.541
Solitary injecting >80 % of the time
No 48 (65 %) 152 (71 %) 0.321 52 (74 %) 154 (73 %) 0.788 1  
Yes 26 (35 %) 62 (29 %)   18 (26 %) 58 (27 %)   1.43 (0.64, 3.18) 0.384
Arrest (since last interview)
No 28 (38 %) 109 (51 %) 0.048* 31 (45 %) 114 (54 %) 0.202 1  
Yes 46 (62 %) 104 (49 %)   38 (55 %) 98 (46 %)   1.53 (0.70, 3.34) 0.281
HCV serology status
Negative 6 (10 %) 43 (24 %) 0.012* 6 (10 %) 19 (11 %) 0.607 1  
Positive 42 (70 %) 87 (49 %)   42 (68 %) 105 (61 %)   4.44 (1.43, 13.73) 0.010*
Exposed 12 (20 %) 47 (27 %)   14 (22 %) 59 (28 %)   1.66 (0.46, 6.01) 0.436
NSP as usual source of syringe acquisition (past month)
No 12 (16 %) 20 (9 %) 0.105 20 (29 %) 31 (15 %) 0.008* 1  
Yes 62 (84 %) 194 (91 %)   50 (71 %) 182 (85 %)   0.27 (0.09, 0.77) 0.015*
  1. Regression number of observations: 215; Prob(chi2): 0.12; R2: 0.14
  2. *Indicates statistically significant result at the <0.05 alpha level (bold data)
  3. aAdjusted Odds Ratio, adjusted for all variables in the table